Table 2. Clinical and pathological characteristics of breast carcinoma in situ in China.
| Characteristics | N | % |
|---|---|---|
| Tumor location | ||
| left | 70 | 48.95 |
| right | 65 | 45.45 |
| Non-palpable | 8 | 5.59 |
| Quadrant | ||
| upper inner | 21 | 14.69 |
| upper outer | 60 | 41.96 |
| lower inner | 6 | 4.20 |
| lower outer | 9 | 6.29 |
| center | 21 | 14.69 |
| others | 13 | 9.09 |
| Tumor size | ||
| <20mm | 62 | 55.36 |
| 20~49mm | 38 | 33.93 |
| ≥50mm | 12 | 10.71 |
| Pathology | ||
| DCIS | 126 | 88.11 |
| LCIS | 10 | 6.99 |
| Paget's disease | 7 | 4.90 |
| ER/PR status | ||
| ER+&PR+ | 64 | 52.46 |
| ER+&PR- | 10 | 8.20 |
| ER-&PR+ | 15 | 12.30 |
| ER-&PR- | 30 | 24.59 |
| unknown | 3 | 2.46 |
| HER2 status | ||
| HER2+ | 34 | 23.78 |
| HER2- | 58 | 40.56 |
| uncertain | 17 | 11.89 |
| unknown | 5 | 3.50 |
ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor-2.